Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle About Us menu options
Our Team
For Patients
Toggle For Patients menu options
About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
Multiple Myeloma
Amyloidosis
Other Plasma Cell Disorders
Toggle Other Plasma Cell Disorders menu options
Precursor Conditions to Multiple Myeloma
Myeloma Signs and Symptoms
Amyloidosis Signs and Symptoms
Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
Multiple Myeloma and Plasma Cell Disorder Treatment
Understanding and Managing Side Effects
Your First Visit
Toggle Your First Visit menu options
Self-Referral
Support Groups and Helpful Links
Frequently Asked Questions
Referring Physicians
Toggle Referring Physicians menu options
Refer a Patient
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 8 results
Author
Title
Type
[
Year
]
Filters:
Author
is
Hajek, Roman
[Clear All Filters]
2014
Palumbo A
,
S Rajkumar V
,
San Miguel JF
,
Larocca A
,
Niesvizky R
,
Morgan G
,
Landgren O
,
Hajek R
,
Einsele H
,
Anderson KC
et al.
. 2014.
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
.
J Clin Oncol. 32(6):587-600.
2015
A Stewart K
,
S Rajkumar V
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Mihaylov GG
et al.
. 2015.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
.
N Engl J Med. 372(2):142-52.
2016
Avet-Loiseau H
,
Fonseca R
,
Siegel D
,
Dimopoulos MA
,
Spicka I
,
Masszi T
,
Hajek R
,
Rosiñol L
,
Goranova-Marinova V
,
Mihaylov G
et al.
. 2016.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
.
Blood. 128(9):1174-80.
A Stewart K
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Niesvizky R
,
Jakubowiak AJ
et al.
. 2016.
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
.
J Clin Oncol. 34(32):3921-3930.
2017
Ludwig H
,
Dimopoulos MA
,
Moreau P
,
Chng W-J
,
Goldschmidt H
,
Hajek R
,
Facon T
,
Pour L
,
Niesvizky R
,
Oriol A
et al.
. 2017.
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
.
Leuk Lymphoma. 58(10):2501-2504.
Dimopoulos MA
,
A Stewart K
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel D
,
Mihaylov GG
,
Goranova-Marinova V
et al.
. 2017.
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
.
Br J Haematol. 177(3):404-413.
Dimopoulos MA
,
Goldschmidt H
,
Niesvizky R
,
Joshua D
,
Chng W-J
,
Oriol A
,
Orlowski RZ
,
Ludwig H
,
Facon T
,
Hajek R
et al.
. 2017.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
.
Lancet Oncol. 18(10):1327-1337.
Castillo JJ
,
Jurczyszyn A
,
Brozova L
,
Crusoe E
,
Czepiel J
,
Davila J
,
Dispenzieri A
,
Eveillard M
,
Fiala MA
,
Ghobrial IM
et al.
. 2017.
IgM myeloma: A multicenter retrospective study of 134 patients.
.
Am J Hematol. 92(8):746-751.